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Abstract of Thesis
Transcriptomic analysis of cytokine-treated tissue-engineered cartilage as an in vitro model of
osteoarthritis
By
Rachel (Jiehan) Li
Master of Science in Biomedical Engineering
Washington University in St. Louis, 2020
Research Advisor: Professor Farshid Guilak

Osteoarthritis (OA), as the most common form of arthritis and a leading cause of disability
worldwide, currently has no disease-modifying drugs. Inflammation plays an important role in
cartilage degeneration in OA, and pro-inflammatory cytokines, IL-1β and TNF-α, have been
shown to induce degradative changes along with aberrant gene expression in chondrocytes, the
only resident cells in cartilage. The goal of this study was to further understand the transcriptomic
regulation of tissue-engineered cartilage in response to inflammatory cytokines using an in vitro
miPSC model system. We performed RNA sequencing for the IL-1β or TNF-α treated tissueengineered cartilage derived from murine iPSCs, and analyzed transcriptomic profiles by
comparing with those of two different osteoarthritis models and human OA cartilage samples. We
investigated differentially expressed genes (DEGs) as well as gene set enrichment and proteinprotein interaction network, showing a significant similarity between model systems and human
OA cartilage. Our analysis revealed a significant number of overlapping DEGs, together with
consistent pathway enrichment in inflammatory response, cytokine-mediated response and
extracellular matrix organization, which support that the murine iPSC model system can replicate
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many of the characteristics of OA cartilage at the transcriptomic level, specifically in the catabolic
aspect of inflammation induce OA. The murine iPSC model system provides a method for studying
the pro-inflammatory response and pathogenesis in OA cartilage, and will be a valuable dataset
for identifying therapeutic targets of inflammation induced OA.

1
Chapter 1:
Introduction
Osteoarthritis (OA) is the most common form of arthritis and a leading cause of disability
worldwide. OA is a chronic joint disease that is characterized not only by degeneration and
calcification of cartilage, but also by subchondral bone sclerosis, osteophyte formation, and joint
inflammation, which lead to symptoms of joint pain, stiffness, and loss of mobility and flexibility
in OA patients (Goldring & Goldring, 2010). Over 10% of men and 13% of women aged 60 and
over are diagnosed with knee OA (Murphy et al., 2008). In 2015, it was estimated that 30.8
million adults suffer from osteoarthritis in the United States (Cisternas et al., 2016). However,
there are no cure of OA currently (W. Zhang, Robertson, Zhao, Chen, & Xu, 2019). Further
insight in transcriptomic profile of osteoarthritic cartilage is critical to development of
therapeutic treatment. This thesis value the capability of murine iPSCs derived tissue-engineered
cartilage to replicate OA environment. In this thesis, total RNA of murine iPSCs derived tissueengineered cartilage in response of pro-inflammation cytokines were extracted, sequenced and
analyzed. Further transcriptomic comparison of iPSC OA model, IL-1β treated murine
chondrocytes, IL-1β and TNF-α treated human OA cartilage, and untreated human OA cartilage
were done with the RNA sequencing data from published online datasets and the RNA seq result
of the iPSC OA model generated in our lab.

1.1 Current Treatment of OA
Current treatment of OA is still mainly limited to pain relievers and anti-inflammatory drugs,
which may alleviate symptoms, but cannot restore the joint function (W. Zhang et al., 2019).
Traditional medications for OA include paracetamol, nonsteroidal anti-inflammatory drugs, and
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opiate analgesics; however, they are limited and only show moderate treatment effects with
potentially adverse side effects and toxicities (Meek, Van de Laar, & H, 2010; W. Zhang et al.,
2019). No disease-modifying osteoarthritis drugs (DMOADs) are currently available, which in
part is due to the fact that the development of DMOADs are limited by the understanding of this
complex chronic joint disease, as well as the lack of good in vitro disease models for drug screening.

1.2 Inflammation in OA
OA has many risk factors such as aging, joint injury or trauma, genetics, obesity, metabolic
disorders and inflammation. Pro-inflammatory cytokines, such as interleukin-1 (IL-1) and tumor
necrosis factor-α (TNF-α), have been shown to play an important role in OA (Goldring & Otero,
2011). These pro-inflammatory cytokines are elevated in synovium, chondrocytes and other
surrounding tissue and induce aberrant expression of catabolic and inflammation-related genes in
an OA joint, which also prevents articular cartilage repair. IL-1β and TNF-α induce cartilage
degradation and inflammation by activating NF-𝜅B signaling, which increases matrix
metalloproteinases and aggrecanase expression, nitric oxide (NO) and prostaglandin E synthase 2
(PGE2) synthesis, and reduces production of extracellular matrix (ECM) components(Goldring &
Marcu, 2009; Studer, Jaffurs, Stefanovic-Racic, Robbins, & Evans, 1999; Wojdasiewicz,
Poniatowski, & Szukiewicz, 2014). A number of anti-inflammatory agents have been developed
as potential therapies for OA or as an approach to inhibit inflammatory effects on cartilage tissue
(Alten et al., 2008; Cohen et al., 2011; Guler-Yuksel et al., 2010; Magnano et al., 2007;
Verbruggen, Wittoek, Vander Cruyssen, & Elewaut, 2012). Although these anti-inflammatory
mediators show promising effects in murine cartilage, most of them failed in clinical trials of
human patients with OA due to limited efficacy and no significant treatment effects compared to
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placebo. Thus, it is critical to further understand the molecular mechanisms in OA cartilage using
disease models for the development of therapeutic interventions.
1.3 Current Models of OA
Common animal models used for OA are the knee joints. Models can be classified by
primary OA (spontaneous models) or Secondary OA (post-trauma and other causes). Primary
OA models closely simulate the natural progression of osteoarthritis development, while
Secondary OA models are conditionally induced osteoarthritis to study specific causes or risk
factors of OA. Secondary OA models can be further classified by surgical or chemical induced
(Kuyinu, Narayanan, Nair, & Laurencin, 2016). Anterior Cruciate Ligament Transection (ACLT)
and Destabilization of the Medial Meniscus (DMM) are two common methods widely used in
OA research, as they are highly reproducible and progress rapidly. Toxic or inflammatory
compounds are also used in OA research for generated chemically induced OA model (Kuyinu et
al., 2016).
In vitro models are essential for drug development for their high tractability, convivence
and rapid progression. Besides mechanical loading, cytokine induction has also been heavily
studied in OA. Two pro-inflammatory cytokines, IL-1β and TNF-α, are the most common
components used to generated OA-like process in cartilage tissue or chondrocytes (Johnson,
Argyle, & Clements, 2016).

1.3 iPSC Model System in OA
Current in vitro models involve treating isolated cells or cartilage explants with cytokines such
as IL-1β or TNF-α (Johnson et al., 2016; Kuyinu et al., 2016). These approaches have provided
important information for the differences in OA compared to healthy tissues, however they lack
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an abundant source of cells or tissues with a controlled genetic background, which is necessary for
high-throughput DMOAD screening. Induced pluripotent stem cells (iPSCs) can aid highthroughput drug screening due to their capacity for extensive expansion as well as consistent
differentiation and genetic tractability (Engle & Puppala, 2013). In previous work, our lab
developed a rigorous protocol to generate tissue-engineered cartilage from murine iPSCs (miPSCs)
(Diekman et al., 2012). Here, we treated tissue-engineered cartilage pellets differentiated from
miPSCs with IL-1β or TNF-α to recapitulate OA environment and investigated transcriptomic
profile of the cytokine treated pellets with RNA sequencing.

5

Chapter 2:
Transcriptomic Analysis of Cytokine-Treated Tissue-Engineered Cartilage as an In Vitro
Model of Osteoarthritis
2.1 Introduction
The goal of this study was to further understand the transcriptomic regulation of tissue
engineered cartilage in response to inflammatory cytokines using an in vitro miPSC model system.
Previous studies (Willard et al., 2014) have shown that some of the characteristics of OA are
recapitulated in murine iPSCs, but the overall effects of IL-1β and TNF-α on the transcriptome are
unknown in comparison to OA cartilage. Thus, we examined the transcriptomic profile of IL-1β
or TNF-α stimulated miPSCs derived tissue-engineered cartilage (pellet.IL or pellet.TNF, Figure
1A), and compared it to publicly available data sets from the National Center of Biotechnology
Information (NCBI) Gene Expression Omnibus (GEO) database and SkeletalVis: (1) IL-1β treated
murine chondrocytes (mchondro.IL, Figure 1B), (2) IL-1β or TNF-α treated human OA cartilage
(OAcartilage.IL or OAcartilage.TNF, Figure 1C), and (3) untreated human OA cartilage
(cartilage.OA, Figure 1D). Differentially expressed genes and gene set enrichment analysis were
performed and were used to evaluate the ability of this in vitro culture system to replicate the
osteoarthritis cartilage. Furthermore, the transcriptomic analysis comparison among different OA
models provided valuable information on target genes and pathways, as well as insights into the
molecular and cellular mechanisms of inflammation in OA.
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Figure 1. Flow chart and overview of 4 datasets used in transcriptomic comparison. (A) RNA
sequencing data from IL-1β or TNF-𝛼 treated tissue engineered cartilage pellets, which were
named as pellet.IL and pellet.TNF separately; (B) RNA sequencing data from mouse IL-1β
treated primary chondrocytes, which was named as mchondro.IL; (C) RNA sequencing data
from IL-1β or TNF-𝛼 human osteoarthritic cartilage, which were named as OAcartilage.IL and
OAcartilage.TNF; (D) RNA sequencing data from human OA cartilage, which were named as
cartilage.OA.
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2.2 Materials and Methods
2.2.1 RNA-Sequencing of Tissue-Engineered Cartilage
Murine iPSCs were chondrogenically differentiated following an established protocol from our
lab (Diekman et al., 2012) and were given 1ng/ml IL-1β, 20ng/ml TNF-α, or control media without
cytokines for 72 hours (Figure 1A). Total cellular RNA was isolated with Total RNA Purification
Plus Kit (Norgen) for mRNA sequencing. Three biological replicates for each condition were
sequenced on Illumina HiSeq3000 (n=3) (Ross et al., 2020). The IL-1β treated iPSC derived
cartilage was designated pellet.IL, while the TNF-α treated group was named pellet.TNF (Figure
1A).

2.2.2 RNA Sequencing Data Information
Gene expression datasets from IL-1β treated murine chondrocytes (GSE104793) and human
OA patient cartilage (GSE114007) were obtained from the National Center of Biotechnology
Information (NCBI) Gene Expression Omnibus (GEO) database (www.ncbi.nlm.nih.gov/geo). In
the dataset GSE104793, primary mouse articular chondrocytes were isolated from mouse cartilage
tissue and cultured with 1 ng/ml IL-1β or control media for 24 hours before cellular RNA isolation
and mRNA sequencing (Son et al., 2017). This group was called mchondro.IL in Figure 1B and
the following part of this paper.
Human OA cartilage mRNA expression profiles in response to cytokine treatment were
obtained from SkeletalVis (http://phenome.manchester.ac.uk/)(Jamie Soul, Boot-Handford,
Schwartz, & University of, 2017; J. Soul, Hardingham, Boot-Handford, & Schwartz, 2019). OA
cartilage explants were harvested from 3 patients with OA at total knee replacement and cultured
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with serum free Dulbecco's modified Eagle's medium (DMEM) for 3 days before treated with
0.1ng/ml IL-1β, 10ng/ml TNF-α, or control media for 72 hours before cellular RNA isolation and
mRNA sequencing (Jamie Soul et al., 2017) (Figure 1C). The IL-1β treated human OA cartilage
was named OAcartilage.IL, and the TNF-α treated OA cartilage was named OAcartilage.TNF in
this paper.
In dataset GSE114007, cartilage samples were harvested from the knee cartilage of 20 patients
with OA and compared to 18 cartilage samples from normal patients without any joint disease or
trauma (Fisch et al., 2018). This group of mRNA sequencing result was named cartilage.OA in
Figure 1D and in the following comparisons.

2.2.3 Data Preprocessing and DEG Screening
The limma package in R was used for differential expression analysis. To find DEGs
(differentially expressed genes), we performed Benjamini-Hochberg multiple testing correction
and the cutoff values for DEG identification were adjusted such that the adjusted P-value was less
than 0.05 (Padj < 0.05) and the absolute value of log2(fold change) (Log2FC) was set as greater than
1 (|Log2FC| > 1) for cytokine treated pellets and untreated human OA cartilage. For cytokine
treated human OA cartilage and IL-1β treated murine chondrocytes, genes were selected with
|Log2FC| > 0.5. Murine gene IDs were mapped to homologous human genes with Mouse Genome
Database (MGD) at the Mouse Genome Informatics website for comparisons between human and
mouse transcriptomic profiles.

2.2.4 Functional and Pathway Analysis
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Gene set enrichment analysis was performed through the Enrichr web-based tool with GO
categories “Biological process 2018” (https://amp.pharm.mssm.edu/Enrichr/)(Chen et al., 2013;
Kuleshov et al., 2016). This analysis was used to provide information about the biological
processes that are significantly enriched in upregulated or downregulated DEGs. A standard FDR
cutoff of 0.05 was used as the cut-off of GO term enrichment.

2.2.5 PPI Network Integration
To investigate the protein-protein interactions (PPI), the STRING database (version 11.0) was
used to construct functional protein association networks. Interaction scores more than 0.70 (high
confidence) were defined as significant. Both up-regulated overlapping DEGs and down-regulated
overlapping DEGs were investigated through STRING, to analysis the major cellular function with
the predicted functional protein-protein interactions.

2.3 Results
2.3.1 Differentially Expressed Genes in Cytokine Treated OA Models and OA Cartilage
From Patients
The analysis of differentially expressed genes was performed with the 4 groups of data
separately, and the mouse and human cartilage gene expression datasets shared 11613 orthologue
gene groups. In pellet.IL, 1781 (849 up-regulated and 932 down-regulated) genes were detected
as differentially expressed genes (DEGs) after treated with IL-1β; while in pellet.TNF, 1174 (635
up-regulated and 512 down-regulated) genes were detected as DEGs after treated with TNF-α. In
mouse mchondro.IL, 1914 (857 up-regulated and 1057 down-regulated) gene were classified as
DEGs. In OAcartilage.IL, 1974 (812 up-regulated and 1162 down-regulated) were detected as
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DEGs, and in OAcartilage.TNF 1565 (780 up-regulated and 785 down-regulated) genes were
detected as DEGs. In cartilage.OA, 1687 (1066 up-regulated and 621 down-regulated) DEGs are
found. Gene names of DEGs for each model and OA cartilage are listed in Supplemental File S1.

Figure 2. Venn diagrams showing shared differentially expressed genes (DEGs). (A) Shared
DEGs in IL-1β treated tissue-engineered cartilage pellets (pellet.IL), murine primary
chondrocytes (mchondro.IL) and human osteoarthritic cartilage (OAcartilage.IL), as well as nontreated human osteoarthritic cartilage (cartilage.OA). 23.9% (427 (=223+110+41+64)
overlapping DEGs / 1781 total DEGs in pellet.IL) of DEGs in pellet.IL are also dysregulated in
mchondro.IL; 23.4% (417 (=188+110+41+78) overlapping DEGs / 1781 total DEGs in pellet.IL)
of DEGs in pellet.IL are differentially expressed in OAcartilage.IL; 22.0% (392
(=209+78+41+64) overlapping DEGs / 1781 total DEGs in pellet.IL) of DEGs in pellet.IL are
differentially expressed in cartilage.OA. (B) Shared DEGs in TNF-𝛼 treated tissue-engineered
cartilage pellets (pellet.TNF) and human osteoarthritic cartilage (OAcartilage.TNF), as well as
non-treated human osteoarthritic cartilage (cartilage.OA). 21.7% (255(=171+84) overlapping
DEGs / 1174 total DEGs in pellet.TNF) of DEGs in pellet.TNF are shared between
OAcartilage.TNF and pellet.TNF. 21.2% % (249(=165+84) overlapping DEGs / 1174 total
DEGs in pellet.TNF) of DEGs in pellet.TNF are also detected as dysregulated genes in cartilage
from OA patients. (C) Shared DEGs pellet.IL, pellet.TNF, OAcartilage.IL, and
OAcartilage.TNF. 47.7% (560(=370+48+118+24) overlapping DEGs / 1174 total DEGs in
pellet.TNF) of DEGs in pellet.TNF overlap with DEGs in pellet.IL, and 72.4%
(1134(=788+78+118+150) overlapping DEGs / 1565 total DEGs in OAcartilage.TNF) of DEGs
in OAcartilage.TNF overlap with DEGs in OAcartilage.IL.

Venn diagrams were used to show the number of shared and different DEGs in groups. Each
model showed more than 20% of shared DEGs compared to other models and OA cartilage
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samples (Figure 2A, B), indicating that these models partially replicate the DEGs from human
OA cartilage. Comparing between different cytokine treatments shows that 47.7% of genes in the
murine iPSC model dysregulated after TNF-α treatment were also differentially expressed with
IL-1β treatment, while 72.4% of DEGs in TNF-α treated human OA cartilage were shared with
DEGs responding to IL-1β treatment (Figure 2C).

Figure 3. Venn diagrams showing number of overlapping upregulated (+) or downregulated (-)
differentially expressed genes (DEGs) between different models. (A) Upregulated (+) or
downregulated (-) DEGs in IL-1β treated tissue-engineered cartilage pellets (pellet.IL) and IL-1β
treated murine primary chondrocytes (mchondro.IL). (B) Upregulated (+) or downregulated (-)
DEGs in IL-1β treated tissue-engineered cartilage pellets (pellet.IL) and IL-1β treated human
osteoarthritic cartilage (OAcartilage.IL). (C) Upregulated (+) or downregulated (-) DEGs in IL1β treated tissue-engineered cartilage pellets (pellet.IL) and human osteoarthritic cartilage
(cartilage.OA). (D) Upregulated (+) or downregulated (-) DEGs in TNF-𝛼 treated tissueengineered cartilage pellets (pellet.TNF) and TNF-𝛼 treated human osteoarthritic cartilage
(OAcartilage.TNF). (E) Upregulated (+) or downregulated (-) DEGs in TNF-𝛼 treated tissueengineered cartilage pellets (pellet.TNF) and human osteoarthritic cartilage (cartilage.OA).
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To better understand the advantages and limitations of tissue-engineered cartilage as a model
system, DEGs were classified by up-regulated or down-regulated and comparisons were made
between cytokine treated tissue-engineered cartilage and IL-1β treated murine chondrocytes,
cytokine treated human OA cartilage or untreated cartilage from OA patients.
When pellet.IL and mchondro.IL were compared, 427 overlapping DEGs were detected with
high significance (p= 4.070184e-19). Among them, 404 genes were regulated in the same direction,
while 23 genes were regulated in opposite direction (Figure 3A). Vnn2, Nos2, Ccl5, Cfb, Ccl20,
Serpina3f, Ch25h, Col10a1, and Matn1 show the highest absolute value of Log2FC in IL-1β
treated pellet among all the overlapping DEGs (Table 1).
Table 1. Top 30 dysregulated genes common to both IL-1β treated pellets (pellet.IL) and IL-1β
treated murine primary chondrocytes (mchondro.IL).
Gene
Name
Vnn3
Nos2

Ccl5
Cfb
Ccl20
Serpina3f
Ch25h

C3
Orm1

Functional Annotation
Vascular non-inflammatory molecule 3;
Amidohydrolase
Nitric oxide synthase; Produces nitric oxide (NO)
and mediates cysteine S- nitrosylation of
PTGS2/COX2.
C-C motif chemokine 5
Complement factor B
C-C motif chemokine 20; Chemotaxis of dendritic
cells, T-cells and B-cells
Serine (or cysteine) peptidase inhibitor, clade A,
member 3F
Cholesterol 25-hydroxylase; Regulating lipid
metabolism, cell positioning and movement in
lymphoid tissues
Complement C3; Activation of the complement
system
Alpha-1-acid glycoprotein 1; Modulates activition
the immune system during the acute-phase
reaction

Log2 Fold Change
pellet.IL
mchondro.IL
8.20
4.30
6.11

6.25

6.10
5.46
5.45

4.33
3.77
2.80

5.45

0.52

5.14

4.94

4.97

5.39

4.89

1.41
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Orm2

Tnfsf15
Lcn2

Gpr84
Tnfrsf9
Gdnf

Tubb2b
Kcnt2
Inhbe
Ucma
Ptgis
Chad
Cmtm5
Frzb

Zfp648
C1qtnf3
Mall
Matn3
Omd
Col10a1
Matn1

Alpha-1-acid glycoprotein 2; Modulates activation
the immune system during the acute-phase
reaction
Tumor necrosis factor ligand superfamily member
15; Mediates activation of NF-kappa-B
Neutrophil gelatinase-associated lipocalin;
Regulation of apoptosis, innate immunity and renal
development.
G-protein coupled receptor 84
Tumor necrosis factor receptor superfamily
member 9
Glial cell line-derived neurotrophic factor; Survival
and morphological differentiation of dopaminergic
neurons
Tubulin beta-2B chain; Major constituent of
microtubules
Potassium channel, subfamily T, member 2
Inhibin beta E chain; TGF-beta family
Unique cartilage matrix-associated protein;
Negative control of osteogenic differentiation
Prostacyclin synthase
Chondroadherin; Promotes attachment of
chondrocytes, fibroblasts, and osteoblasts.
CKLF-like MARVEL transmembrane domain
containing 5
Secreted frizzled-related protein 3; Antagonist of
Wnt8 signaling. Regulates chondrocyte maturation
and long bone development
Zinc finger protein 648
C1q and tumor necrosis factor related protein 3
MAL-like protein; T cell differentiation protein-like
Matrilin-3; Major component of the extracellular
matrix of cartilage
Osteomodulin; Involved in biomineralization
Collagen alpha-1(X) chain; Product of hypertrophic
chondrocytes
Cartilage matrix protein; binds to collagen

4.86

1.04

4.83

0.97

4.79

2.72

4.72
4.52

2.97
1.61

4.42

0.71

-2.90

-1.32

-2.92
-3.03
-3.13

-1.21
-0.88
-1.05

-3.25
-3.31

-0.64
-1.52

-3.34

-2.18

-3.34

-1.93

-3.35
-3.47
-3.70
-4.90

-1.11
-3.68
-1.08
-2.5

-4.99
-5.27

-1.50
-2.52

-5.79

-3.30

Similarly, when pellet.IL and OAcartilage.IL were compared, 417 overlapping DEGs were
detected with high significance (p= 1.933738e-10). Among them, 330 genes were regulated in the
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same direction, while 87 genes were regulated in opposite direction (Figure 3B). Saa1, Nos2, Ccl5,
Cxcl1, Ccl20, Ch25h, Csf3, Tnip3, Draxin6, Il6, Col10a1, and Omd show the highest absolute
value of Log2FC in IL-1β treated pellet among all the overlapping DEGs (Table 2). However, in
comparison of mchondro.IL and cartilage.OA, 276 overlapping DEGs were detected, which is
non-significant (p= 0.5694874), Among these DEGs, 94 genes were regulated in the same
direction and 182 genes were regulated in the opposite direction (Appendix Figure 1.A).
Table 2. Top 30 dysregulated genes common to both IL-1β treated pellets (pellet.IL) and IL-1β
treated human osteoarthritic cartilage (OAcartilage.IL).
Gene
Name

Functional Annotation

Saa1

Serum amyloid A-1 protein; Major acute phase
protein
Nitric oxide synthase; Produces nitric oxide (NO)
and mediates cysteine S- nitrosylation of
PTGS2/COX2.
C-C motif chemokine 5
neutrophil activation during inflammation
C-C motif chemokine 20; Chemotaxis of dendritic
cells, T-cells and B-cells
Cholesterol 25-hydroxylase; Regulating lipid
metabolism, cell positioning and movement in
lymphoid tissues
Granulocyte colony-stimulating factor
TNFAIP3 interacting protein 3
Chemorepulsive axon guidance protein; an
antagonist of Wnt signaling pathway
Interleukin-6
Collagenase 3; Degradation of extracellular matrix
proteins
Neutrophil gelatinase-associated lipocalin;
Regulation of apoptosis, innate immunity and
renal development.
Solute carrier family 15 member 3; Proton
oligopeptide cotransporter.
G-protein coupled receptor 84

Nos2

Ccl5
Cxcl1
Ccl20
Ch25h

Csf3
Tnip3
Draxin
Il6
Mmp13
Lcn2

Slc15a3
Gpr84

Log2 Fold Change
pellet.IL
OAcartilage.IL
7.76
3.03
6.11

1.71

6.10
5.90
5.45

2.50
3.24
3.70

5.14

2.07

5.11
5.11
5.09

3.51
2.09
2.68

5.07
4.91

4.53
3.41

4.79

2.31

4.76

1.02

4.72

2.56

15
Tnfrsf9
Ptgis
Clec3a
Fam43b
Chad
Cmtm5
Frzb

C1qtnf3
Ogn
Cytl1
Pthlh
Adamtsl2
Nxph3
Matn3
Omd
Col10a1

Tumor necrosis factor receptor superfamily
member 9
Prostacyclin synthase
C-type lectin domain family 3 member A;
Promotes cell adhesion to laminin and fibronectin
Family with sequence similarity 43, member B
Chondroadherin; Promotes attachment of
chondrocytes, fibroblasts, and osteoblasts.
CKLF-like MARVEL transmembrane domain
containing 5
Secreted frizzled-related protein 3; Antagonist of
Wnt8 signaling. Regulates chondrocyte maturation
and long bone development
C1q and tumor necrosis factor related protein 3
Mimecan; Induces bone formation in conjunction
with TGF-beta-1 or TGF-beta-2
Cytokine-like protein C17
Parathyroid hormone-related protein; Regulation
of endochondral bone development
ADAMTS-like 2
Neurexophilin-3
Matrilin-3; Major component of the extracellular
matrix of cartilage
Osteomodulin; Involved in biomineralization
Collagen alpha-1(X) chain; Product of hypertrophic
chondrocytes

4.52

2.38

-3.25
-3.26

-1.46
-5.33

-3.26
-3.31

-1.95
-4.16

-3.34

-2.41

-3.34

-3.02

-3.47
-3.60

-2.02
-4.17

-3.62
-3.64

-2.66
-1.53

-4.02
-4.64
-4.90

-1.68
-1.88
-3.94

-4.99
-5.27

-3.75
-2.90

When pellet.IL and cartilage.OA were compared, 392 overlapping DEGs were detected with
high significance (p= 1.075255e-20). Among them, 170 genes were regulated in the same direction,
and 222 genes were regulated in opposite direction (Figure 3C). Mmp9, Cybb, C1qtnf7, Tnip3,
Mmp13, Tnfsf15, Tnfrsf9, Gdnf, Tnfsf11, Traf3ip3, Gm12695, Adamtsl2, and Peg10 show the
highest absolute value of Log2FC in IL-1β treated pellet among all the overlapping DEGs between
IL-1β treated tissue-engineered cartilage pellet and untreated human osteoarthritic cartilage
(Table 3). Comparison of overlapping DEGs in OAcartilage.IL and cartilage.OA revealed a
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significant overlapping (p= 0.01509899) of 336 DEGs: 142 of them were regulated in the same
direction and 194 DEGs responded differently to IL-1β (Appendix Figure 1.B).

Table 3. Top 30 dysregulated genes common to both IL-1β treated tissue-engineered pellets
(pellet.IL) and human osteoarthritic cartilage (cartilage.OA).
Gene
Name
Mmp9
Cybb
C1qtnf7
Tnip3
Mmp13
Tnfsf15
Tnfrsf9

Gdnf

Tnfsf11
Traf3ip3
S100a8
Tnfsf8
Msr1
Atp8b3
Mme
Myzap
Tinagl1
Stc2
Kcnk5

Functional Annotation
Matrix metalloproteinase-9; Bone osteoclastic
resorption
Cytochrome b-245 heavy chain; Membranebound oxidase of phagocytes
C1q and tumor necrosis factor related protein 7
TNFAIP3 interacting protein 3
Collagenase 3; Degradation of extracellular matrix
proteins
Tumor necrosis factor ligand superfamily member
15; Mediates activation of NF-kappa-B
Tumor necrosis factor receptor superfamily
member 9
Glial cell line-derived neurotrophic factor; Survival
and morphological differentiation of dopaminergic
neurons
Tumor necrosis factor ligand superfamily member
11; Osteoclast differentiation and activation
factor.
TRAF3-interacting JNK-activating modulator;
TRAF3-mediated JNK activation
Protein S100-A8; regulation of inflammatory
processes and immune response
Tumor necrosis factor ligand superfamily member
8;Induces proliferation of T-cells
Macrophage scavenger receptor types I
Phospholipid-transporting ATPase IK
Neprilysin; Destruction of opioid peptides
Myocardial zonula adherens protein
Tubulointerstitial nephritis antigen-like
Stanniocalcin-2
Potassium channel, subfamily K, member 5

Log2 Fold Change
pellet.IL
cartilage.OA
7.97

5.13

5.96
5.59
5.11

3.29
1.01
2.59

4.91

3.69

4.83

5.21

4.52

2.06

4.42

2.86

4.13

2.01

4.08

1.39

3.83

3.75

3.83
3.69
3.56
3.48
-1.94
-1.95
-2.00
-2.16

2.47
3.47
1.27
3.44
-2.41
-1.95
-2.42
-1.53
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Slc37a2
Gprc5a
Ndnf
Kcnt2

Myoc
Ucma
Cytl1
Arhgef37
Peg10
Adamtsl2
Gm12695

Glucose-6-phosphate exchanger SLC37A2
Retinoic acid-induced protein 3; A negative
modulator of EGFR signaling
Protein NDNF; Promotes matrix assembly and cell
adhesiveness
Potassium channel, subfamily T, member 2
Myocilin; Negatively regulates cell-matrix
adhesion and stress fiber assembly through Rho
protein signal transduction
Unique cartilage matrix-associated protein;
Negative control of osteogenic differentiation
Cytokine-like protein C17
Rho guanine nucleotide exchange factor 37
Retrotransposon-derived protein PEG10; Inhibits
the TGF-beta signaling
ADAMTS-like 2
C1orf87 homolog; C1orf87, calcium ion binding

-2.26

-1.59

-2.38

-2.20

-2.41
-2.92

-1.06
-1.03

-3.12

-2.85

-3.13
-3.62
-3.65

-2.50
-1.66
-1.69

-3.80
-4.02
-4.37

-1.24
-1.90
-1.22

For the TNF-α treated model, when pellet.TNF and OAcartilage.TNF were compared, 255
overlapping DEGs were detected with a highly significant value (p= 3.079532e-12). Among them,
221 genes were regulated in the same direction, while 34 genes were regulated in opposite direction
(Figure 3D). Ccl5, Il2rg, Cxcl2, Ccl20, Cfb, Tnip3, Gpr84, Il1f9, and Slc15a3 show the highest
absolute value of Log2FC in TNF-α treated pellet among all the overlapping DEGs (Table 4).

Table 4. Top 30 dysregulated genes common to both TNF-𝛼 treated tissue-engineered cartilage
pellets (pellet.TNF) and TNF-𝛼 treated human osteoarthritic cartilage (OAcartilage.TNF).
Gene
Name

Functional Annotation

Ccl5
Il2rg

C-C motif chemokine 5
Cytokine receptor common subunit gamma
C-X-C motif chemokine 2; Chemotactic for
human polymorphonuclear leukocytes
C-C motif chemokine 20; Chemotaxis of
dendritic cells, T-cells and B-cells

Cxcl2
Ccl20

Log2 Fold Change
pellet.TNF OAcartilage.TNF
8.15
5.00
7.30
1.70
7.03

2.25

6.75

4.34
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Cfb
Tnip3
Gpr84
Il1f9
Slc15a3

Traf1
Cxcl10

Nos2
Mmp10
Slc7a11
Slc2a6
C1qtnf3

Gdf10

Thbs2
Aqp3
Adamtsl2
Fxyd3
Smim5
Col1a1
Sv2b
Nxph4

Tub
Mfap4
Ndufa4l2

Complement factor B
TNFAIP3 interacting protein 3
G-protein coupled receptor 84
Interleukin-36 gamma; an agonist of NF-kappa B
activation
Solute carrier family 15 member 3; Proton
oligopeptide cotransporter.
TNF receptor-associated factor 1; Adapter
molecule that regulates the activation of NFkappa-B and JNK.
C-X-C motif chemokine 10; a proinflammatory
cytokine
Nitric oxide synthase; Produces nitric oxide (NO)
and mediates cysteine S- nitrosylation of
PTGS2/COX2.
Stromelysin-2; Can degrade fibronectin, gelatins
and collagens. Activates procollagenase
Cystine/glutamate transporter
Solute carrier family 2 (facilitated glucose
transporter)
C1q and tumor necrosis factor related protein 3
Growth/differentiation factor 10; Inhibits
osteoblast differentiation via SMAD2/3
pathway.
Thrombospondin-2; Adhesive glycoprotein that
mediates cell-to-cell and cell-to-matrix
interactions
Aquaporin-3; Water channel
ADAMTS-like 2
FXYD domain-containing ion transport regulator
3
Small integral membrane protein 5
Collagen alpha-1(I) chain; Type I collagen
Synaptic vesicle glycoprotein 2B
Neurexophilin
Tubby protein; Functions in signal transduction
from heterotrimeric G protein-coupled
receptors.
Microfibril-associated glycoprotein 4; Elastic
fiber assembly andmaintenance
NADH dehydrogenase (ubiquinone) 1 alpha
subcomplex, 4-like 2

6.11
6.09
6.07

1.08
2.75
2.30

5.92

2.70

5.05

1.57

4.99

2.55

4.85

4.79

4.78

2.06

4.74
4.63

1.94
2.21

4.42
-1.88

2.3012152
-1.2424457

-1.89

-2.5585607

-1.91
-2.03
-2.15

-1.62
-0.71
-1.42

-2.20
-2.25
-2.34
-2.34
-2.55

-1.46
-1.42
-1.37
-1.94
-1.34

-2.82

-1.05

-3.37

-3.08

-3.39

-1.62
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Chrdl2
Car9

Chordin-like protein 2; negatively regulates
cartilage formation/regeneration
Carbonic anhydrase 9; Reversible hydration of
carbon dioxide. Participates in pH regulation

-3.65

-2.47

-4.79

-1.52

When pellet.TNF and cartilage.OA were compared, 249 overlapping DEGs were detected with
a highly significant value (p= 6.401139e-15). Among them, 121 genes were regulated in the same
direction, while 128 genes were regulated in opposite direction (Figure 3E). In comparison of
overlapping DEGs in TNF-α treated human osteoarthritic cartilage and untreated human
osteoarthritic cartilage, 227 overlapping DEGs were detected with a significant value of 0.003
(p=0.003104403). Among them, 123 genes are regulated in the same direction and 154 genes
respond differently to TNF-α (Appendix Figure 1.C). Mmp9, Cybb, Tnip3, Nlrp3, Tmem132e,
Aldh1a2, and Msr1 showed the highest absolute value of Log2FC in TNF-α treated pellet among
all the overlapping DEGs between pellet.TNF and cartilage.OA (Table 5). The rest of the
overlapping DEGs are regulated in same direction and listed in Supplemental File S1.

Table 5. Top 30 dysregulated genes common to both TNF-𝛼 treated tissue-engineered cartilage
pellets (pellet.TNF) and untreated human osteoarthritic cartilage (cartilage.OA).
Gene
Name
Mmp9
Cybb
Tnip3
Nlrp3
Tmem132
e
Aldh1a2

Functional Annotation
Matrix metalloproteinase-9; Bone osteoclastic
resorption
Cytochrome b-245 heavy chain; Membranebound oxidase of phagocytes
TNFAIP3 interacting protein 3
NACHT, LRR and PYD domains-containing protein;
Innate immunity and inflammation
Transmembrane protein 132E
Retinal dehydrogenase 2

Log2 Fold Change
pellet.TNF cartilage.OA
7.03

5.13

6.90
6.09

3.29
2.59

5.32

1.86

5.04
4.51

1.41
1.13
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Msr1

Gdnf
Vegfc
Ptges
Adtrp
Tnfrsf9
S100a8
AA467197
C1qtnf7
Pfkfb3

Pdk1
Vit
Necab3
Ramp1
Egln3
Stc2
Peg10
Pck1
Irf4

Bnip3
Adamtsl2
Slc16a3
Apln
Ankrd37

Macrophage scavenger receptor types I
Glial cell line-derived neurotrophic factor; Survival
and morphological differentiation of
dopaminergic neurons
Vascular endothelial growth factor C;
Angiogenesis and endothelial cell growth
Prostaglandin E synthase; Catalyzes the
oxidoreduction of PGH2 to PGE2
Androgen-dependent TFPI-regulating protein
Tumor necrosis factor receptor superfamily
member 9
Protein S100-A8; regulation of inflammatory
processes and immune response
Normal mucosa of esophagus-specific gene 1
protein
C1q and tumor necrosis factor related protein 7
6-phosphofructo-2-kinase/fructose-2,6biphosphatase 3
Pyruvate dehydrogenase (acetyl-transferring)]
kinase isozyme 1; regulation of glucose and fatty
acid metabolism
Vitrin; Promotes matrix assembly and cell
adhesiveness
N-terminal EF-hand calcium-binding protein 3
Receptor activity-modifying protein 1; receptor
for calcitonin-gene-related peptide (CGRP)
Egl nine homolog 3; DNA damage response
Stanniocalcin-2
Retrotransposon-derived protein PEG10; Inhibits
the TGF-beta signaling
Phosphoenolpyruvate carboxykinase, cytosolic
[GTP]
Interferon regulatory factor 4; Transcriptional
activator
BCL2/adenovirus E1B 19 kDa protein-interacting
protein 3; Apoptosis-inducing protein that can
overcome BCL2 suppression.
ADAMTS-like 2
Monocarboxylate transporter 4
Apelin; modulate immune responses in neonates
Ankyrin repeat domain 37

4.28

3.47

3.71

2.86

3.65

1.98

3.31
3.20

1.77
1.97

3.16

2.06

3.09

3.75

3.08
3.00

2.73
1.01

-1.51

-2.38

-1.51

-1.53

-1.54
-1.54

-2.24
-1.25

-1.54
-1.67
-1.69

-1.50
-1.74
-2.42

-1.74

-1.24

-1.95

-2.62

-1.99

-2.20

-2.13
-2.15
-2.50
-2.74
-3.02

-1.91
-1.90
-1.20
-1.08
-2.24
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We also compared DEGs in response of different cytokines treatment, IL-1β or TNF-α. In
iPSC model system, 560 overlapping genes were detected with a highly significant value (p=
7.52312e-181). Among them, 487 genes were regulated in the same direction while 73 genes were
regulated in the opposite direction. In IL-1β and TNF-α treated human osteoarthritic cartilage,
there were 1105 overlapping DEGs, and all of them were in the same direction (Appendix Figure
1.D, E).

2.3.2 Pathway Analysis in Cytokine-Treated OA Model and OA Cartilage From Patients
To gain further insight into the shared and differentially expressed biological processes and
mechanisms, gene set enrichment analysis was performed using the up-regulated and downregulated DEGs. In total, each group of DEGs generated more than 20 significant GO terms, most
of which were involved in biological processes related to extracellular matrix organization,
cytokines stimuli, and inflammatory response. Annotated GO terms were ranked by P value, and
terms with lowest P value in each group of DEGs were shown in Figure 4. The whole table of
annotated GO term for each model and OA cartilage are provided in Supplemental File 2.
Pathways related to cellular response to various stimuli, such as “GO: 0019221 Cytokinemediated signaling pathway”, “GO: 0071345 Inflammatory response”, and “GO: 0032496
Response to lipopolysaccharide” were generally annotated in up-regulated DEGs of all cytokine
treated models and untreated OA cartilage, while they were only highly ranked in cytokine treated
models (Figure 4 and Supplemental File 2). Overlapping genes in these terms included Ccl5,
Ccl20, Chad, Lif, Nfkbia, Ripk2, Sod2, Tnfaip3, and Tnfrsf9 et al (Appendix Table 1, 2).
Cartilage related biological processes, such as “GO: 0030198 Extracellular matrix organization”
and “GO:0001501 Skeletal system development” were generally annotated in most groups.
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However, “GO: 0030198 Extracellular matrix organization” was only annotated in up-regulated
DEGs rather than down-regulated DEGs of OA cartilage (Figure 2 and Supplemental File 2).
Overlapping genes in these terms included collagen family, Hapln1, matrilin family, and Sox9, et
al (Appendix Table 1, 2).
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Figure 4. Top gene ontology (GO) terms and pathways identified by functional enrichment
analysis through Enrichr and GO Biological Process 2018, (top 10 ranked by P value). (A)
Upregulated (+) and downregulated (-) differentially expressed genes (DEGs) in IL-1β treated
tissue-engineered cartilage pellets (pellet.IL) (B) Upregulated (+) and downregulated (-) DEGs in
IL-1β treated murine primary chondrocytes (mchondro.IL). (C) Upregulated (+) and
downregulated (-) DEGs in IL-1β treated human osteoarthritic cartilage (OAcartilage.IL). (D)
Upregulated (+) and downregulated (-) DEGs in human osteoarthritic cartilage (cartilage.OA).
(E) Upregulated (+) or downregulated (-) DEGs in TNF-𝛼 treated tissue-engineered cartilage
pellets (pellet.TNF). (F) Upregulated (+) or downregulated (-) DEGs in TNF-𝛼 treated human
osteoarthritic cartilage (OAcartilage.TNF).

2.3.3 PPI Network in Cytokine Treated OA Model and OA Cartilage From Patients
To further examine the common DEGs that characterize OA models and OA cartilage samples,
protein-protein interaction (PPI) networks for common genes shared by different models and OA
cartilage were established through STRING with interaction score ≥ 0.70 (high confidence), with
all disconnected nodes are hidden in the network. Reactome pathway assessment was also done in
STRING to reveal the significant biological pathways in overlapping DEGs.
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For common DEGs that were co-directionally regulated in IL-1β treated tissue-engineered
cartilage pellet (pellet.IL) and IL-1β treated murine primary chondrocytes (mchondro.IL), there
were mainly 4 clusters of genes in the PPI network (Figure 5). These included clusters of genes
that were related to the extracellular matrix (Collagen family, Itga10 et al.), cell cycle and mitosis
(Ccna2, Ube2c, Nuf2, Spc25 et al.), the immune system (H-2 class I histocompatibility complex,
Orosomucoid, Cd14, Ikbke, et al.), and signal transduction (C-C Motif Chemokine Ligands, Kng1,
C3, Gng2, Ptger4 et al.).

Figure 5. PPI network between differentially expressed genes (DEGs) that regulated in the same
direction in two different groups, as established in STRING. DEGs common to both IL-1β
treated tissue-engineered cartilage pellets (pellet.IL) and IL-1β treated murine primary
chondrocytes (mchondro.IL), interaction score ≥ 0.90, disconnected nodes were hidden in the
network. Reactome pathway assessment of these genes were down in STRING, and nodes were
colored with the Reactome pathway. Color labels of pathways were shown in legend table at lefttop of the figure.
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For co-directionally regulated overlapping genes in IL-1β treated tissue-engineered cartilage
pellet (pellet.IL) and IL-1β treated human OA cartilage (OAcartilage.IL), the cluster of
extracellular matrix related genes was maintained, while the scale of signal transduction related
genes cluster was reduced. Groups of NF-κB signal related genes and glycosaminoglycan
metabolism proteins were shown with more interconnections (Figure 6).

Figure 6. PPI network between differentially expressed genes (DEGs) that regulated in the same
direction in two different groups, as established in STRING DEGs common to both IL-1β treated
tissue-engineered cartilage pellets (pellet.IL) and IL-1β treated human osteoarthritic cartilage
(OAcartilage.IL), interaction score ≥ 0.90, disconnected nodes were hidden in the network.
Reactome pathway assessment of these genes were down in STRING, and nodes were colored
with the Reactome pathway. Color labels of pathways were shown in legend table at left-top of
the figure.
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There were fewer overlapping genes in IL-1β treated tissue-engineered cartilage pellet
(pellet.IL) and untreated human OA cartilage (cartilage.OA), and the PPI network lost the
extracellular matrix related cluster as the collagen family genes were regulated in different
directions (Figure 7). However, groups of ADAMTS and matrix metalloproteinase were shown
in the network.

Figure 7. PPI network between differentially expressed genes (DEGs) that regulated in the same
direction in two different groups, as established in STRING DEGs common to both IL-1β treated
tissue-engineered cartilage pellets (pellet.IL) and human osteoarthritic cartilage (cartilage.OA),
interaction score ≥ 0.70, disconnected nodes were hidden in the network. Reactome pathway
assessment of these genes were down in STRING, and nodes were colored with the Reactome
pathway. Color labels of pathways were shown in legend table at left-top of the figure.

Similarly, in the PPI network for the TNF-α treated tissue-engineered cartilage pellet
(pellet.TNF) and TNF-α treated human OA cartilage (OAcartilage.TNF), there was a compact
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cluster of extracellular matrix related genes and small clusters of signal transduction related genes,
mainly C-C Motif Chemokine Ligands and NF-κB signal related genes (Figure 8).

Figure 8. PPI network between differentially expressed genes (DEGs) that regulated in the same
direction in two different groups, as established in STRING. DEGs common to both TNF-𝛼
treated tissue-engineered cartilage pellets (pellet.TNF) and TNF-𝛼 treated human osteoarthritic
cartilage (OAcartilage.TNF), interaction score ≥ 0.90, disconnected nodes were hidden in the
network. Reactome pathway assessment of these genes were down in STRING, and nodes were
colored with the Reactome pathway. Color labels of pathways were shown in legend table at lefttop of the figure.
The reactome pathway assessment of co-directionally regulated overlapping genes network in
TNF-α tissue-engineered cartilage pellet (pellet.TNF) and untreated human OA cartilage
(cartilage.OA) revealed that matrix metalloproteinase and vascular endothelial growth factor were
the central of the network, while no collagen family or NF-κB signaling pathway were found with
reactome pathway assessment (Figure 9).
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Figure 9. PPI network between differentially expressed genes (DEGs) that regulated in the same
direction in two different groups, as established in STRING. DEGs common to both TNF-𝛼
treated tissue-engineered cartilage pellets (pellet.TNF) and human osteoarthritic cartilage
(cartilage.OA), interaction score ≥ 0.70, disconnected nodes were hidden in the network.
Reactome pathway assessment of these genes were down in STRING, and nodes were colored
with the Reactome pathway. Color labels of pathways were shown in legend table at left-top of
the figure.

2.3.4 Osteoarthritis Pathway
An inflammation-induced OA signaling pathway was generated with the overlapping genes
comparing transcriptomic profiles of all the OA groups, both in response to IL-1β and TNF-α
stimuli and untreated OA cartilage samples (Supplemental File 3). Furthermore, biological
processing annotation of the list was done to create a network of the genes within the inflammationinduced OA signaling pathway (Figure 10). The extracellular matrix related pathway
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(Extracellular matrix organization, collagen fibril organization), skeletal system development, cell
proliferation related signaling (regulation of cell proliferation, MAPK signaling pathways,
activation of protein kinase activity), cellular response to cytokines and response to
lipopolysaccharide were each identified as predominant signaling pathways in inflammation
induced OA.

Figure 10. OA pathway generated from the common genes and enriched pathways in
OAcartilage.IL, pellet.IL, and cartilage.OA, together with the common genes and enriched
pathways in OAcartilage.TNF, pellet.TNF, and cartilage.OA. (A) Common genes –
GO:BioProcess network of OA. (B) log2 fold change of genes in the network.

2.4 Discussion
In this study, we compared the transcriptomic profiles of IL-1β and TNF-α treated tissueengineered cartilage pellets differentiated from murine iPSCs, IL-1β treated murine primary
chondrocytes, IL-1β and TNF-α treated human OA cartilage, and cartilage from osteoarthritis
patients to identify the abilities and limitations of in vitro OA models in replicating OA. Our
findings show that the miPSC-based in vitro model replicates many of the transcriptomic
characteristics of native cartilage treated with cytokines, as well as those of cartilage from OA
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patients. The comparison of differentially expressed genes and pathway enrichment of multiple
OA models and OA cartilage from patients also provides further insight into the effects of
inflammation in osteoarthritis and creates opportunities to develop new therapeutic approaches for
osteoarthritis treatment.
Through quantitative comparisons of overlapping DEGs and pathways, we valued the overall
similarities and differences between cytokine treated in vitro OA models and untreated cartilage
from OA patients. There have been a number of previous studies investigating DNA
methylation(Jeffries et al., 2014; Moazedi-Fuerst et al., 2014), transcriptomics (Dunn et al., 2016;
Fisch et al., 2018; Lv et al., 2019; Ren et al., 2018; Steinberg et al., 2017), and protein
expression(Liao et al., 2018) in OA models or in cartilage from OA patients. However, most of
these studies only characterized their OA disease model in terms of the expression of specific
genes (Zhong, Huang, Karperien, & Post, 2016). A few studies integrated -omics datasets (DNA
CpG methylation, RNA sequencing, and quantitative proteomics) (Steinberg et al., 2017) or
conducted transcriptomics comparisons between different OA animal models and OA cartilage (J.
Soul et al., 2019). Here, we found the differentially expressed genes in various cytokine-induced
OA models and untreated OA cartilage and quantified the overlapping DEGs (Figure 2). Both
comparisons between IL-1β and TNF-α and various OA models showed a relatively large amount
of overlapping DEGs, especially in comparison between response to different cytokines in same
model system (Figure 2,3). A core set of dysregulated genes among all datasets predominantly
involved Col2a1, col11a1, col9a1 (collagen family), Nfkb2, Nfkbie, Tnfrsf9, Tnip1, Tnip3 (NF-κB
signaling), Mmp13, and Timp1(Matrix Metallopeptidase). These results support previous findings
that IL-1β and TNF-α treated tissue-engineered cartilage can replicate the inflammation-induced
loss of homeostasis and dysregulation of extracellular matrix proteins.
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Gene set enrichment analysis of up-regulated and down-regulated DEGs revealed the most
significant terms in each OA model and OA cartilage sample. In total, 34 GO biological processing
terms were annotated in all datasets, which mainly involved cellular response to cytokine stimulus,
inflammatory response, extracellular matrix organization and disassembly, immunity, MAPK
cascade, cell proliferation, and apoptotic process (Supplemental file 2). Furthermore, the PPI
networks established with overlapping genes further indicated that three major cluster of genes
were common in most comparisons: NF-κB family (inflammation signaling), collagenase family
and matrix metallopeptidase (Extracellular matrix organization) and cemokine ligands (Figure 59). These results further supported the finding that the response of murine iPSC differentiated
tissue-engineered cartilage pellets to pro-inflammatory cytokines replicated the transcriptomic
expression changes in OA cartilage in inflammation related pathways, and thus provide a model
system for finding potential targets for future therapies and approaches to overcome the
inflammatory environment in OA.
By comparing gene expression changes in response to IL-1β and TNF-α treatment in different
OA models, we were able to generate a list of common genes that are highly related to an
inflammation-induced OA signaling pathway (Figure 10, Supplemental File 3). These genes
revealed the core signaling mediators in inflammation-induced OA. The cytokine stimulus and
inflammatory related genes play a crucial role in the OA inflammation pathway, which is
consistent with a number of previous cartilage pathway studies, e.g. Tnfsf11 (Li et al., 2012), Nfkb2
(Boyce, Yao, & Xing, 2010), Fosl1 (Dunn et al., 2016), Cebpb (Hirata et al., 2012).
Our data also suggested that dysregulation of ECM components (Col1a1, Col1a2, Col2a1,
Col5a1, Col9a1) and proteases (Mmp9, Mmp13) involved in ECM remodeling may be active as
part of the inflammatory response in OA pathogenesis. Previous studies have shown that the
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dysregulation of collagens plays a crucial role in the chondron-remodeling and cartilage
degeneration in osteoarthritis (Luo et al., 2017). Type II collagen (Col2a1) is the major component
that forms the highly dense collagen fibril network in cartilage, while collagen type IX and XI, as
minor components, fill in this proteoglycan matrix (Xia et al., 2014). Type X collagen (Col10a1)
has been shown as a marker of chondrocyte hypertrophy (Zheng et al., 2003) and observed in
hypertrophic zone and calcified zone in cartilage and also in arthritis cartilage (Gannon et al., 1991;
Shen, 2005). Mmp9 (gelatinase B) is upregulated in hypertrophic chondrocytes, which degrades
gelatin (Rose & Kooyman, 2016; Vu et al., 1998). Mmp13 (Collagenase-3) is highly overexpressed at early stage of OA cartilage and induced extracellular matrix degradation in cartilage
(Burrage, Mix, & Brinckerhoff, 2006). Timp3, an inhibitor of Mmp13, reduces the activity of
Collagenase-3(Knauper, Lopez-Otin, Smith, Knight, & Murphy, 1996). Wnt and Rho GTPase
signaling has been implicated in chondrocyte hypertrophy and final maturation in previous studies
(Day, Guo, Garrett-Beal, & Yang, 2005; Dell'accio, De Bari, Eltawil, Vanhummelen, & Pitzalis,
2008; Wang & Beier, 2005), which has been shown dysregulated in our study. Sox9, as an
important transcription factor in chondrocytes differentiation, has been shown to repress the
expression of ADAMTS at the early stage of OA (Q. Zhang et al., 2015). Regulation of cell
proliferation and apoptosis is also responsible for cartilage degeneration in OA (Sun et al., 2015).
Igf1 actives phosphorylation states of ERK1/2 or Akt signaling (McMahon, Prendergast, &
Campbell, 2008; Montaseri et al., 2011). Igf2 has been shown to reduce loss of chondrocytes,
osteophyte formation and subchondral bone thickening in vivo injury induced mouse OA
(Uchimura, Foote, Smith, Matzkin, & Zeng, 2015). Clec3a encodes tetranectin and is also detected
as a DEG in multi-omics OA study (Steinberg et al., 2017), in addition to being implicated in
osteogenesis and bone mineralization in a previous study (Wewer et al., 1994).
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2.5 Limitations
A limitation in our findings is that this iPSC OA model only partially replicates the gene
expression changes in real OA cartilage. There were hundreds of unshared DEGs and DEGs
regulated in different orientations in models and in OA cartilage. Specifically, we found that the
cluster of collagen family genes were up-regulated in cartilage from OA patients while downregulated in all in vitro models. These differences could be due to a number of factors. First, OA
is a complex whole-joint disease, which can be caused by various risk factors, such as trauma or
injury (Thomas, Hubbard-Turner, Wikstrom, & Palmieri-Smith, 2017), aging (Loeser, 2009),
obesity (Courties, Gualillo, Berenbaum, & Sellam, 2015), and inflammation (Courties et al., 2015).
Although most of them lead to similar symptoms or cartilage phenotype, different etiologies are
involved in the OA development. Nonetheless, we found that these in vitro models replicated the
catabolic aspects of pro-inflammatory environment in OA cartilage, and thus can serve as a
research tool to future development of therapy and drug screening. While an inflammation-induced
OA model will not completely replicate the multiple factors that lead to clinical OA, such models
still serve as the primary in vitro system for research and OA drug screening. Second, there are
different stages of OA, and many studies have shown that specific genes can be up- or downregulated at earlier or later stages of the disease (Loeser et al., 2013; Zhong et al., 2016). Third, in
the joint of OA patients, there are multiple cell types and tissues interacting with each other in vivo,
which may affect gene expression changes in chondrocytes in response to stimuli. For example,
synovial mesenchymal stem cells have been shown to alleviate osteoarthritis by promoting
proliferation when co-cultured with meniscus chondrocytes(Qiong, Xia, Jing, & Haibin, 2020).
Finally, the concentrations of cytokines also affect gene expression changes in models with
variations over time. Studies of cytokine treated tissue-engineered cartilage with multiple time
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points showed that increasing numbers of DEGs (772 to 1781 genes with IL-1β and 612 to 1147
genes with TNF-α) and that there were groups of genes with different temporal patterns of
expression from 4 hour to 72 hour post-treatment (Ross et al., 2020).
2.6 Conclusion
Overall, our data support that cytokine treated tissue-engineered cartilage can replicate many
of the characteristics of OA cartilage at the transcriptomic level. As this model represents the
cytokine related regulation in OA cartilage degeneration, it can be used to identify targets in the
inflammatory response, cellular response to cytokines, and NF-κB signaling pathways. Thus, it
provides a model for studying the pro-inflammatory response and pathogenesis in OA cartilage,
and will be a valuable dataset for identifying therapeutic targets for inflammation induced OA
treatment. The ability of self-renewal and unlimited proliferation of iPSCs offers this model the
possibility of high-throughput drug screening with a defined genotype. Also, this transcriptomic
analysis comparison of OA disease models and human OA cartilage provides us with a further
understanding of the systematic mechanism and molecular and cellular basis of inflammation in
OA.
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Appendix Figure 1: Venn diagrams showing number of overlapping upregulated (+) or
downregulated (-) DEGs between different models

(A) Comparison of IL-1β treated murine chondrocytes (mchondro.IL) and untreated human
osteoarthritic cartilage (cartilage.OA) showed 276 overlapping DEGs: 94 are regulated in the
same direction, while 182 genes respond differently. (B) Comparison of IL-1β treated human
osteoarthritic cartilage (OAcartilage.IL) and untreated human osteoarthritic cartilage
(cartilage.OA) showed 336 overlapping DEGs: 142 are regulated in the same direction, while
194 genes respond differently. (C) Comparison of TNF-𝛼 treated human osteoarthritic cartilage
(OAcartilage.TNF) and untreated human osteoarthritic cartilage (cartilage.OA) showed 277
overlapping DEGs: 123 are regulated in the same direction, while 154 genes respond differently.
(D) Comparison of IL-1β treated tissue-engineered cartilage pellets (pellet.IL) and TNF-𝛼 treated
tissue-engineered cartilage pellets (pellet.TNF) showed 560 overlapping genes: 478 are regulated
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in the same direction, while 73 genes respond differently. (E) Comparison of IL-1β treated
human osteoarthritic cartilage (OAcartilage.IL) and TNF-𝛼 treated human osteoarthritic cartilage
(OAcartilage.TNF) showed 1105 overlapping genes with co-directionally regulation.

Appendix Table 1: Common genes of gene ontology (GO) terms in response of IL-1β
Term

DEGs in four study groups

extracellular matrix organization (GO:0030198)

FGF2; HAPLN1; SH3PXD2B; CYP1B1; COL10A1;
GREM1; COL2A1; MATN4; CD44; MATN3;
COL11A1; COL11A2; LAMB3; ITGA10; COL9A1;
COL9A3; COL9A2
IL1RN; FGF2; TNFSF11; SOX9; IFNAR2; PTGIS;
IL1R1; IRAK3; ASPN; CEBPD; CCL5; CHAD; CCL20;
LIF; LCN2; SDC1; PTPN2
IL1RN; HFE; FGF2; TNFSF11; IFNAR2; IL1R1;
CHAD; TNFRSF9; LIF; NFKBIA; LCN2; SDC1; RIPK2;
IRAK3; ASPN; CD44; CEBPD; CCL5; CCL20; SOD2;
FAS
COL11A2; HAPLN1; PAPSS2; FRZB; SH3PXD2B;
COL10A1; SOX9; GDF10; IGF1; COL2A1; COL9A2;
MATN3; CD44
FGF2; FTH1; CYP1B1; SOX9; SCIN; ABL1;
TNFRSF9; LIF; IGF1; NGF; GREM1; FRZB; SOD2;
FAS; PTPN2
FGF2; SOX8; SOX9; GREM1; CCL5; LIF; IGF1

cellular response to cytokine stimulus (GO:007134
5)
cytokinemediated signaling pathway (GO:0019221)

skeletal system development (GO:0001501)

regulation of cell proliferation (GO:0042127)

positive regulation of cell proliferation (GO:00082
84)
response to lipopolysaccharide (GO:0032496)
negative regulation of cell proliferation (GO:00082
85)
regulation of cell migration (GO:0030334)
regulation of epithelial cell proliferation (GO:0050
678)

TNFAIP3; PDE4B; CD14; GCH1; TNFRSF9; IRAK3;
TNIP1; FAS; TRIB1
TNFAIP3; FTH1; CYP1B1; SOX9; NGF; GREM1;
TRIB1; FBLN1; SCIN; FRZB; SOD2; GDF5; PTPN2
RND3; CYP1B1; CCL5; IGF1; SOD2
IGF1; GDF5; SOX9

Common genes of gene ontology (GO) terms from functional enrichment analysis from GO
Biological Process 2018 with DEGs in all 4 group of studies, IL-1β treated tissue-engineered
cartilage pellets (pellet.IL), IL-1β treated murine primary chondrocytes (mchondro.IL), IL-1β
treated human osteoarthritic cartilage (OAcartilage.IL) and untreated human osteoarthritic
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cartilage (cartilage.OA).

Appendix Table 2: Common genes of gene ontology (GO) terms in response of TNF-𝛼
Term

DEGs in three study groups

extracellular matrix organization (GO:0030198)

CYP1B1; COL2A1; COL11A1; COL11A2; COL9A1;
COL9A3; COL9A2
RIPK2; IFNGR2; CCL5; CHAD; CCL20; TNFSF15;
TNFRSF9; LIF; SOD2; NFKBIA; FAS
TNFAIP3; PDE4B; MEF2C; GCH1; TNFRSF9;
TNIP1; FAS
GCH1; TNFRSF9; TNFAIP3; FAS

cytokinemediated signaling pathway (GO:0019221)
response to lipopolysaccharide (GO:0032496)
response to molecule of bacterial origin (GO:00022
37)
cellular response to cytokine stimulus (GO:007134
5)
skeletal system development (GO:0001501)
regulation of cell proliferation (GO:0042127)
negative regulation of apoptotic process (GO:0043
066)
positive regulation of cell proliferation (GO:000828
4)
collagen fibril organization (GO:0030199)

PTGIS; IFNGR2; CCL5; CHAD; CCL20; LIF
COL11A2; PAPSS2; FRZB; GDF10; COL2A1;
COL9A2
FTH1; CYP1B1; SCIN; FRZB; TNFRSF9; LIF; SOD2;
MDM2; FAS
SOX8; MEF2C; RIPK2; SOD2; NFKBIA; FAS
SOX8; MEF2C; CCL5; LIF; MDM2
COL2A1; COL11A1; COL11A2; CYP1B1

Common genes of gene ontology (GO) terms from functional enrichment analysis from GO
Biological Process 2018 with DEGs in all 3 group of studies, TNF-𝛼 treated tissue-engineered
cartilage pellets (pellet.TNF), TNF-𝛼 treated human osteoarthritic cartilage (OAcartilage.TNF)
and untreated human osteoarthritic cartilage (cartilage.OA).

